-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 05-31-2026 TO 06-06-2026
I’m excited to announce the release of my latest free bio tech stock catalyst report for the upcoming week. This new free stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock…
$BYSI, $CGEM, $CING, $CRDF, $CUE, $EQ, $VOR, 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, 2026 Jefferies Global Healthcare Conference, biopharmaceutical, clinical-research, EULAR 2026 Congress (European Congress of Rheumatology), fda, new drug application, pr-newswire, press-releases, Webcast -
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 05-24-2026 TO 05-30-2026
I’m excited to announce the release of my latest free bio tech stock catalyst report for the upcoming week. This new free stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock…
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 05-17-2026 TO 05-23-2026
I’m excited to announce the release of my latest free bio tech stock catalyst report for the upcoming week. This new free stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock…
$CGON, $CRBP, $FATE, $NBP, $NMRA, $TNXP, $VTGN, $ZNTL, A.G.P.’s Annual Virtual Healthcare Conference, biopharmaceutical, clinical-research, fda, H.C. Wainwright 4th Annual BioConnect Investor Conference, ISPOR 2026, new drug application, pr-newswire, press-releases, RBC Capital Markets Global Healthcare Conference, Stifel 2026 Virtual Oncology Forum -
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 05-03-2026 TO 05-09-2026
I’m excited to announce the release of my latest free bio tech stock catalyst report for the upcoming week. This new free stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock…
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 03-01-2026 TO 03-07-2026
We’re excited to announce the release of our latest free bio tech stock catalyst report for the upcoming week. This new free stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock…
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 02-22-2026 TO 02-28-2026
We’re excited to announce the release of our latest free bio tech stock catalyst report for the upcoming week. This new free stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock…
$ALDX, $ALXO, $BBIO, $CGEN, $FULC, $GANX, $IMRX, $TARA, $XNCR, ASCO Genitourinary Cancers Symposium, biopharmaceutical, clinical-research, fda, new drug application, Oppenheimer 36th Annual Healthcare Life Sciences Conference, pr-newswire, press-releases, Wells Fargo Executive Biotech Summit, World ADC London 2026 -
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 02-08-2026 TO 02-14-2026
Well well, The Seattle Seahawks take the Win in Super Bowl LX. This is what Google’s Gemini summarized regarding stock market prediction after the Win. And now, back to the BIO-TECH STOCK CATALYST REPORT. We’re excited to announce the release of our latest free bio tech stock catalyst report for the upcoming week. This new…
-
Insmed to Present Fourth Quarter and Full Year 2025 Financial Results
NASDAQ: $INSM Insmed Incorporated has officially announced the schedule for its upcoming financial results presentation. The company will host a conference call to discuss its financial performance for the fourth quarter and the entirety of the fiscal year 2025. This event is set to take place on Thursday, February 19, 2026. The conference call is…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 02-01-2026 TO 02-07-2026
The Groundhog sees his shadow, so hunker down and trade more to warm up! 😉 We’re excited to announce the release of our latest bio tech stock catalyst report for the upcoming week. This new stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions…
$AMGN, $AZN, $BMY, $BSX, $DNLI, $GKOS, $GSK, $INCY, $JAZZ, $LLY, $MRNA, $PHVS, $REGN, $SNY, biopharmaceutical, clinical-research, fda, new drug application, pr-newswire, press-releases -
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 01-18-2026 TO 01-24-2026
We’re excited to announce the release of our latest bio tech stock catalyst report for the upcoming week. This new stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock quote page…
$ABBV, $AZN, $ELDN, $GMAB, $GNLX, $LLY, $LTRN, $MNKD, $NOV, $NVO, $NVS, $PFE, $SNY, biopharmaceutical, clinical-research, fda, new drug application, pr-newswire, press-releases -
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF SEPTEMBER 28, 2025 – OCTOBER 04, 2025
September 28, 2025 EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE $ Clinical Trial 09/30/2025 AGEN 53.89 6,179 0.00 Clinical Trial 09/30/2025 BTAI 53.32 4,080 0.00 PDUFA 09/30/2025 FBIO 28.17 1,996 0.00 Clinical Trial 09/30/2025 ALEC 25.87 730 0.00 Clinical Trial 09/30/2025 STRO 44.79 170 0.00 Clinical Trial 09/30/2025 RCKT 34.65 2,506…
-
Sarepta Therapeutics Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne
NASDAQ: $SRPT Sarepta Therapeutics (NasdaqGS: $SRPT) is at the forefront of innovation in the treatment of Duchenne Muscular Dystrophy (DMD) with its groundbreaking gene therapy, ELEVIDYS. As a rare, progressive genetic disorder, DMD significantly impairs muscle function and can lead to severe health complications. In an effort to provide new hope to affected individuals and…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF FEBRUARY 2, 2025 – FEBRUARY 08, 2025
EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE $ Data Release 02/03/2025 IVVD 55.1 44 0.36 Conference 02/05/2025 ANAB 30.6 2,770 17.93 Conference 02/05/2025 CABA 22.5 12,509 2.39 Conference 02/05/2025 ABSI 23.2 14,305 3.71 Conference 02/06/2025 PRAX 33.6 13,932 76.55 Conference 02/06/2025 FBRX 23.4 504 15.89 Conference 02/06/2025 ADCT 32.3 172 1.68…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF JANUARY 26, 2025 – FEBRUARY 01, 2025
EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE $ Conference 01/28/2025 LXRX 49.9 4,606 0.99 Conference 01/28/2025 IPA 28.7 3,588 0.58 Webinar 01/29/2025 OTLK 21.0 1,839 1.99 Corporate Event 01/29/2025 ZNTL 58.3 4,312 2.22 FDA Event 01/30/2025 VRTX 17.34 48,375 439.62 FDA Event 01/31/2025 AXSM 13.99 45,376 103.11 Clinical Trial 02/01/2025 SUPN…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF DECEMBER 29, 2024 – JANUARY 04, 2025
EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE $ FDA Event 12/29/2024 NBIX 4.2 1,817 139.44 FDA Event 12/29/2024 BMY 2.5 5,932 57.68 Clinical Trial 12/30/2024 BCLI 42.3 782 2.45 FDA Event 12/30/2024 NBIX 4.2 1,817 139.44 Clinical Trial 12/31/2024 ALDX 13.0 6,889 4.94 Clinical Trial 12/31/2024 ABBV 2.1 6,221 178.01 Clinical…
-
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
NASDAQ: $CKPT Introduction Checkpoint Therapeutics, a leading biopharmaceutical company, recently made a significant announcement regarding the FDA acceptance of the Biologics License Application (BLA) resubmission of Cosibelimab for the treatment of advanced cutaneous squamous cell carcinoma. This development marks a crucial milestone in the ongoing efforts to provide effective treatment options for patients battling this…
-
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine; PDUFA goal date is January 31 2025
NASDAQ: $AXSM Axsome Therapeutics, a leading biopharmaceutical company, has recently announced the exciting news that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the New Drug Application (NDA) for AXS-07 for the acute treatment of migraine. With the FDA acceptance of the NDA resubmission, Axsome Therapeutics is one step closer to…
-
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolR?-targeted ADC, on January 4, 2024
NASDAQ: $STRO 1. Introduction to Sutro Biopharma’s Investor Webcast Welcome to the article covering the upcoming investor webcast hosted by Sutro Biopharma on January 4, 2024. This webcast aims to highlight the potential multi-cancer opportunity associated with Luvelta, a promising FolR?-targeted Antibody-Drug Conjugate (ADC) developed by Sutro Biopharma. In this article, we will delve into…
-
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
NASDAQ: $CGEM 1. Introduction to CLN-617: A Novel Fusion Protein The field of oncology research continues to evolve with the aim of developing innovative and effective therapies to combat cancer. In this regard, Cullinan Oncology has recently announced the initiation of a Phase 1 clinical trial to evaluate the potential of CLN-617, a novel fusion…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF DECEMBER 10-16, 2023
December 10, 2023 EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE Conference 12/10/2023 AUTL 21.1 4,281 $4.36 Conference 12/10/2023 BLUE 26.9 18,165 $2.86 Conference 12/10/2023 BMEA 43.0 49,731 $16.89 Announcement 12/11/2023 COGT 28.9 11,224 $8.64 Conference 12/11/2023 BLUE 26.9 18,165 $2.86 Conference 12/11/2023 HARP 35.3 295 $8.94 Conference 12/14/2023 BCYC 24.0 2,878…
-
Kura Oncology | Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial
NASDAQ: $KURA SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (NASDAQ: $KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and The Leukemia & Lymphoma Society (LLS), the largest private funder of blood cancer research, today announced a clinical collaboration to evaluate Kura’s…
-
Calliditas Therapeutics | The FDA Decision To Convert The Accelerated Approval of Calliditas Therapeutics’ Tarpeyo To Full Approval, December 20, 2023
NASDAQ: CALT 1. Introduction to Calliditas Therapeutics and Tarpeyo Calliditas Therapeutics is a renowned pharmaceutical company focused on developing innovative therapies to address unmet medical needs. One of their notable products is Tarpeyo, a drug designed to provide significant benefits to patients suffering from a specific medical condition. The accelerated approval granted by the FDA…
-
KALA BIO | Stock Price Up Today 43%+, Get Ready For A Move
NASDAQ: KALA Introduction to KALA BIO and its recent stock performance Investors and traders have been closely monitoring the recent surge in KALA BIO’s stock price, which has seen a remarkable 43% increase. KALA BIO, a pharmaceutical company focused on developing innovative therapies, has captured the attention of the market with its promising advancements. In…
-
Vanda Pharmaceuticals | Announces U.S. FDA Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis
NASDAQ: VNDA 1. Introduction to Vanda Pharmaceuticals’ new drug application for Tradipitant Vanda Pharmaceuticals, a leading biopharmaceutical company, has recently announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for Tradipitant, a potential breakthrough treatment for gastroparesis. This acceptance marks a significant milestone in Vanda Pharmaceuticals’ efforts…
-
Neurocrine Biosciences | Hosting Analyst Day on December 5, 2023
NASDAQ: $NBIX Neurocrine Biosciences to Host Analyst Day on December 5, 2023 Have you heard the news? Neurocrine Biosciences, a leading biopharmaceutical company, is set to host an Analyst Day on December 5, 2023. This highly anticipated event will bring together analysts, investors, and industry experts to explore Neurocrine Biosciences’ latest developments and future prospects.…